| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2008 |
How Do You Solve a Problem Like Manufacturing? Outsourcing saves pharmaceutical companies money -- except when it doesn't. Here's how to decide what to do.   |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
Pharmaceutical Executive
April 1, 2011 |
The Big Business of Boosting Performance Dutch-based DSM N.V. is seeking innovative ways to partner through bolstering manufacturing. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
Pharmaceutical Executive
October 1, 2008
Patrick Clinton |
Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there? |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
Chemistry World
June 21, 2010
Sarah Houlton |
Recalling pharma Recent drug withdrawals and manufacturing failures have highlighted the importance of ensuring that the medicines patients take contain what it says on the label. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
Pharmaceutical Executive
January 1, 2012
Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Pharmaceutical Executive
November 1, 2011
Jill Wechsler |
The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Pharmaceutical Executive
September 1, 2006
Jill Wechsler |
Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
September 1, 2006 |
Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
Pharmaceutical Executive
August 1, 2013
William Looney |
Breaching the Great Wall With a revision of China's basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. |
Pharmaceutical Executive
December 1, 2005
Jill Wechsler |
Washington Report: Big Production Drug manufacturing costs too much and is cumbersome to regulate. FDA's answer: Quality by design, which shifts the emphasis from testing the final product to building quality into the manufacturing process from the beginning. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
February 21, 2008
Brian Lawler |
A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
IndustryWeek
August 1, 2002
Tonya Vinas |
Locations -- R.I. Plants To Supply Key Drug Immunex Corp. chooses West Greenwich for BioNext Project, which will produce Enbrel and other drugs for the growing biotech company. |
The Motley Fool
July 28, 2004
Brian Gorman |
Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge. |
IndustryWeek
December 1, 2008
Jill Jusko |
Focus on the Process Industries: Pharmaceuticals: Reworking the Pharma Supply Chain As multiple forces challenge the pharmaceutical industry, supply chains get a new look. |
Pharmaceutical Executive
January 1, 2014
Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
Chemistry World
November 2, 2011
Rebecca Trager |
Escalating Drug Dearth Spooks White House Manufacturing problems are the principal reason for the rapid growth in drug shortages. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
Chemistry World
October 23, 2013
Sarah Houlton |
Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 18, 2009
Brian Orelli |
Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Food Engineering
September 3, 2007
Jim Getchell |
Globalization: Where in the World is Your Supply Chain? Globalization and outsourcing offer opportunities and risks for US food manufacturers striving to optimize their supply chains. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
The Motley Fool
December 18, 2009
Brian Orelli |
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond. |
Pharmaceutical Executive
September 1, 2006 |
Thoughtleader: Small Cost, Big Win CEO J.J. Finkelstein discusses why outsourcing suits RegeneRx, how he manages to stay in control of operations, and why he's still able to sleep at night. |
